<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403087</url>
  </required_header>
  <id_info>
    <org_study_id>BCSHPAE</org_study_id>
    <nct_id>NCT04403087</nct_id>
  </id_info>
  <brief_title>Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications</brief_title>
  <official_title>Additive Effect of Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications; an Open-label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuncheon Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chuncheon Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adverse events related to the eradication medication is one of the reason of lower
      eradication success in the H. pylori treatment. The aim of this study was to evaluate the
      additive effect of trimebutine for the development of adverse events related to the H. pylori
      eradication regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall compliance of eradication medication</measure>
    <time_frame>2 weeks after prescription of eradication medication</time_frame>
    <description>How much the enrolled subjects took prescribed eradication medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to eradication medication</measure>
    <time_frame>2 weeks and 6 weeks after prescription of eradication medication</time_frame>
    <description>percentage of Adverse events related to eradication medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Trimebutine add group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of Trimebutine on the Bismuth-containing quadruple regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Bismuth-containing quadruple regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimebutine 100 MG</intervention_name>
    <description>Trimebutine 100mg three times a day</description>
    <arm_group_label>Trimebutine add group</arm_group_label>
    <other_name>Polybutine (Samil Pharm.Co.,Ltd.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who underwent upper gastrointestinal endoscopy and were proven to have H.
             pylori infection either by using the rapid urease test, the 13 C-urea breath test
             (UBT), or histological examination.

        Exclusion Criteria:

          -  Subjects who took medications as Proton pump inhibitor, Histamin-2 receptor antagonist
             and antibiotics,

          -  Subjects who underwent stomach resection

          -  Subjects less than 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon</state>
        <zip>24253</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Chang Seok Bang, MD, PHD</last_name>
      <phone>+821052657810</phone>
      <email>cloudslove@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Cho Won Kim, MS</last_name>
      <phone>+82332405000</phone>
      <email>kimcw0731@hallym.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chuncheon Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Chang Seok Bang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimebutine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

